

Anti-CEACAM5/CEA/CD66e Antibody (Tusamitamab ravtansine)

Introduction

Tusamitamab ravtansine (SAR408701) is a targeted ADC for CEACAM5-expressing tumor cells, consisting of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent maytansinoid DM4 via a cleavable linker. The average drug-to-antibody ratio (DAR) of tusamitamab ravtansine is 3.8.

Product parameters

Alternative Names	SAR408701
Target Accession	P06731
Target	CEACAM5 / CEA / CD66e
CAS number	2254086-60-5
Molecular Weight	144.52 kDa
Host	CHO
Reactivity	Human, Cynomolgus [US9617345]
Conjugation	DM4
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human CEACAM5 / CEA / CD66e HEK293 Cell Line were stained Anti-CEACAM5 / CEA / CD66e Reference Antibody (Tusamitamab ravtansine) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.61 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

